Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
Zacks Investment Research | Jan 06, 2020 09:35PM ET
Myriad Genetics, Inc. (NASDAQ:MYGN) announced the publication of a new analysis of the GUIDED clinical trial, using the 6-item Hamilton Depression Rating Scale (HAM-D6).
The primary finding was that the HAM-D6 scale identified statistically significant improvements across all three clinical endpoints — remission, response and symptoms – between GeneSight-guided care and treatment-as-usual at the end of the eighth week.
The result of this clinical trial is a major stride forward in the company’s commitment toward strengthening its portfolio of depressive disorder treatments.
More About the Study Results
The GUIDED study was the largest clinical prospective study evaluating the advantages of pharmacogenomics-guided treatment for depression using the GeneSight Psychotropic test over the use of an active therapy control arm.
As part of the GUIDED study protocol, all patients in the study had the 17-item HAM-D17 questionnaire administered. The 6-item HAM-D6 score represents a subset of HAM-D17 questions that have a more direct link to depression.
Clinical studies have shown that the HAM-D6 score is better equipped than HAM-D17 at distinguishing antidepressants from placebo. The scale has also proved to be a superior measure of core depressive symptoms than the HAM-D17 scale. This newly-published analysis also proves that the GeneSight test has resulted in significant and clinically relevant improvements in patients suffering from chronic depressive disorders compared to treatment-as-usual care.
Recent Developments
Lately, Myriad Genetics witnessed a crucial development pertainingtothe GeneSight Psychotropic test.
In November 2019, the company had announced the publication of a new analysis of the GUIDED clinical trial. The key finding was that the GeneSight Psychotropic test led to statistically significant improvement of clinical outcomes across all three endpoints — remission, response and symptoms — in patients taking medications with gene-drug interactions.
Price Performance
In the past three months, the company’s shares have underperformed the industry . The stock has lost 2.5% against the industry’s 22% growth.
Zacks Rank and Stocks Worth a Look
Myriad Genetics currently has a Zacks Rank #4 (Sell).
Get The News You Want
A few better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) . While Haemonetics sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.